Objective:To explore prognostic lncRNA related with fatty acid metabolism,immune response and drug sensitivity in hepatocellular carcinoma(HCC).Methods:Bioinformatics was used to obtain HCC gene data of TCGA database,most prognostic lncRNA were screened out,and prognostic model was constructed,whose accuracy was verified by ROC curve and nomogram.GO and KEGG were used for biological analysis of lncRNA.GSVA and TMB were used to analyze immune status and mutant genes of HCC patients.TIDE score was used to analyze benefit of immunotherapy in HCC patients to identify potentially effective drugs for HCC.Results:Four lncRNAs(AC074117.1,TMCC1-AS1,LINC01063,MKLN1-AS)related to fatty acid metabolism were identified.K-M curve and ROC curve confirmed that stage and risk score could evaluate prognosis of HCC patients.Nomogram confirmed accuracy of the model prediction;GO and KEGG analysis confirmed abundant biological functions of lncRNA related to fatty acid metabolism.GSVA analysis showed that plasma cells,B cells,neutrophils,NK cells and type Ⅱ-IFN response were significantly different between two risk groups.Patients with low TMB and low risk had the best prognosis.TIDE score of high-risk group was significantly higher than that of low-risk group.Five anticancer drugs more suitable for high-risk population were screened out,namely cyclopamine,rapamy-cin,Proteasome inhibitor,paclitaxel and sunitinib.Conclusion:Prediction model constructed by 4 fatty acid metabolism-related lncRNAs helps to evaluate prognosis of HCC and may provide insights for clinical application and immunotherapy of HCC patients.

Hepatocellular carcinoma （HCC）， an insidious malignant tumor with high incidence and lethality， poses a major threat to physical and mental health of human beings. The pathological mechanism needs to be further studied. Surgery， radiotherapy， chemotherapy， and targeted drugs are effective but induce many adverse reactions. Traditional Chinese medicine （TCM） has unique advantages and abundant clinical experience in the treatment of HCC. There has been an explosion of research on the pathways， targets， and mechanism of TCM against HCC from the perspective of molecular biology. According to previous research， Chinese medicinals or compound Chinese medicine prescriptions， directly or indirectly prevent the occurrence and progression of HCC through multiple pathways and targets， which is closely related to the pathophysiological processes such as cell proliferation， metastasis， apoptosis， autophagy， inflammatory response， and immune response. This paper summarizes and analyzes research on the action pathways and mechanisms of Chinese medicine against HCC. Specifically， isoliquiritigenin， dendrobium candidum and Yexiazhu compound Ⅱ regulate phosphatidylinositol 3-kinase/protein kinase B （PI3K/Akt） signaling pathway to inhibit the growth， proliferation and metastasis of tumor cells. Toad venom and dioscorea zingiberensis induce and enhance HCC autophagy by modulating mammalian target of rapamycin （mTOR） signaling pathway. Myricetin， asparagus， and Biejiajian Wan regulate mitogen-activated protein kinase （MAPK） signaling pathway to promote HCC cell cycle arrest， inhibit angiogenesis， and induce apoptosis. Polygonum odoratum， tetragonum， and plantainoside modulate nuclear factor-kappa B （NF-κB） to inhibit inflammatory response and HCC metastasis and reduce drug resistance. Quercetin and erigeron breviscapus control the Janus kinase 2/signal transducer and activator of transcription 3 （JAK2/STAT3） signaling pathway to suppress epithelial-mesenchymal transition （EMT） and remodel cytoskeleton. This paper is expected to lay a theoretical basis for the in-depth research on and clinical application of Chinese medicine in the treatment of HCC.

Traditional surgical resection, radiotherapy, and chemotherapy still play a dominant role in the treatment of liver cancer; however, their application in liver cancer patients is often limited by the toxic and side effects, unstable efficacy, and unclear targets of chemotherapeutic drugs. Therefore, in order to improve the efficacy of drugs in the treatment of liver cancer, nanomedicine, which has been developed in the biomedical field in recent years, has attracted more and more attention. Nano-drug delivery system has been gradually applied in clinical research for its advantages of low toxicity, wide bioavailability, controllable drug release, and good stability. This article focuses on the latest research advances in nano-drug delivery system in the treatment of liver cancer.